Cargando…
Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the primary progressive subtype of MS. Clinical success has increased interest in the role of B cells in the patho...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862116/ https://www.ncbi.nlm.nih.gov/pubmed/33551958 http://dx.doi.org/10.3389/fneur.2020.595547 |